We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Dynorphin Drives Anxiety

News   May 30, 2018 | Original Story by Chris Palmer for Cold Spring Harbour

 
Neuropeptide of Stress: Dynorphin drives anxiety

Anxiety was traced by the CSHL team to the brain's central amygdala, and to increased excitation of neurons that express the peptide somatostatin (SOM+ neurons). This initial step is demonstrated in these images, by comparing the amount of pink and blue fluorescence in the bottom right frame as compared with the frame directly above it, showing the central amygdala in mice not experiencing anxiety. The full pathway involves additional steps and identifies dynorphin, a signaling molecule, as a possible anti-anxiety drug target.

 
 
 

RELATED ARTICLES

Brain Cancer Potentially Resists Immunotherapies by Trapping T Cells in Bone Marrow

News

Certain brain cancers are associated with low numbers of immune system T-cells circulating in the peripheral blood. Low T-cell numbers can be a side-effect of cancer treatment. But it now appears that there is more to the story of these missing T-cells.

READ MORE

A Research Partnership to Find Treatments for Neurological Disorders

News

BioMotiv and Cure Network Dolby Acceleration Partners launch a collaboration to find better treatments for brain disorders.

READ MORE

Novel Histone-Tracking Tool Unlocks New Insights into Epigenetic Cellular Memory

News

The way daughter cells inherit histones is a highly controlled process, and may be highly influential on development.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE